Overview
Black Diamond Q3 net loss narrows to $8.5 mln from $15.6 mln last year
Company's cash position at $135.5 mln, sufficient to fund operations into Q4 2027
R&D expenses decreased due to workforce efficiencies and outlicensing
Outlook
Company plans to release ORR and treatment duration data for silevertinib this quarter
Black Diamond expects FDA feedback on silevertinib path in H1 2026
Company has cash to fund operations into Q4 2027
Result Drivers
R&D EXPENSES - Decrease in R&D expenses attributed to workforce efficiencies and outlicensing of BDTX-4933
G&A EXPENSES - Reduction in G&A expenses due to restructuring efforts
SILEVERTINIB DEVELOPMENT - Focus on silevertinib development in NSCLC and GBM, with upcoming clinical data releases
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$8.50 mln | ||
Q3 Basic EPS | -$0.15 | ||
Q3 Cash & Investments | $135.50 mln | ||
Q3 Income From Operations | -$10.98 mln | ||
Q3 Operating Expenses | $10.98 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $9.00, about 57% above its November 5 closing price of $3.87
Press Release: ID:nGNX67SFrZ
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)